This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers

This study has been completed.
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: October 20, 2008
Last updated: July 1, 2013
Last verified: July 2013
The objective of the study is to assess the PK, safety and tolerability of a single dose of mirabegron alone and in combination with repeat doses of rifampin, a potent CYP3A4 inducer.

Condition Intervention Phase
Pharmacokinetics of YM178 Drug: mirabegron Drug: rifampin Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Phase 1, Open-Label, Drug Interaction Study to Evaluate the Effect of Repeat Doses of Rifampin on the Single-Dose Pharmacokinetics of Mirabegron (YM178)

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Assess pharmacokinetics of mirabegron alone and in combination with rifampin [ Time Frame: One month ]

Secondary Outcome Measures:
  • Assess safety and tolerability of mirabegron alone and in combination with rifampin [ Time Frame: one month ]

Enrollment: 24
Study Start Date: October 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
mirabegron alone
Drug: mirabegron
Other Name: YM178
Experimental: 2
mirabegron and rifampin
Drug: mirabegron
Other Name: YM178
Drug: rifampin
Other Name: Rifadin

Detailed Description:
A single group of patients will receive both mirabegron alone and in combination with rifampin

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Weighs at least 45 kg and body mass index (BMI) between 18 and 32 kg/m2 at Screening
  • Normal or not clinically significant 12 lead ECG and clinical laboratory test results at Screening
  • Female subjects must be post-menopausal, surgically sterile since at least 1 month prior to screening, or practicing effective non-hormonal contraceptive methods. All females must be non-lactating, and should have a negative result for the pregnancy test at Screening and on Day -1
  • Negative drug and alcohol screens

Exclusion Criteria:

  • Has known or suspected hypersensitivity to mirabegron or rifampin
  • Liver enzyme test abnormalities (ALT, AST, or bilirubin) above the upper limit of normal
  • History or presence of psychiatric illness, serious active or recurrent infection or hepatitis
  • Previous history of cancer other than basal cell carcinoma or Stage 1 squamous cell carcinoma that has not been in remission for at least 5 years prior to the dose of study drug
  • Donation or loss of ≥ 450 mL blood within 56 days prior to study drug administration or has donated plasma within 7 days prior to study drug administration
  • Received or is anticipated to receive a prescription drug within 14 days prior to Day -1 or within 30 days prior to Day -1 for any long acting treatments. Use of any over-the-counter medications, including complementary and alternative medicines (except for occasional use of acetaminophen of up to 2000 mg/day but not more than 4 days per week) within 14 days prior to Day -1
  • History of substance abuse within 6 months prior to Screening
  • Current participation in another clinical trial or is taking or has been taking an investigational drug in the 30 days or 10 half lives of the drug, whichever is longer, prior to dosing
  • Known to have hepatitis or HIV-1 and/or HIV-2 or is positive for hepatitis A antibody IgM, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody at Screening
  • Subject has consumed alcohol, caffeine-containing food or beverages, grapefruit juice, grapefruit-containing products or Seville oranges within 48 prior to Day -1
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00776516

United States, Florida
Miami, Florida, United States, 33126
Sponsors and Collaborators
Astellas Pharma Inc
Study Director: Central Contact Astellas Pharma Global Development
  More Information

Additional Information:
Responsible Party: Astellas Pharma Inc Identifier: NCT00776516     History of Changes
Other Study ID Numbers: 178-CL-070
Study First Received: October 20, 2008
Last Updated: July 1, 2013

Keywords provided by Astellas Pharma Inc:
Healthy volunteer subjects
CYP3A4 inducer
drug interaction

Additional relevant MeSH terms:
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP3A Inducers
Adrenergic beta-3 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Urological Agents processed this record on July 21, 2017